www.fiercebiotech.com Open in urlscan Pro
104.18.1.165  Public Scan

Form analysis
2 forms found in the DOM

GET /search-results

<form action="/search-results" method="get">
  <div class="container">
    <div class="row mb-4">
      <div class="col-11">
        <div class="text-left element-title xlarge">What are you searching for?</div>
      </div>
      <div class="col-1 search-dismiss align-items-center d-flex justify-content-end"><button type="button" data-dismiss="modal" class="search-modal-toggle"><img src="/themes/custom/quartz_barrio/images/icons/times-regular.svg"
            alt="Dismiss search modal" style="min-width: 30px;"></button></div>
    </div>
    <div class="row search-form mb-4">
      <div class="col d-flex align-items-center"><button class="position-absolute search-modal-submit" type="submit"><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="search" class="svg-inline--fa fa-search fa-w-16" role="img"
            xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512">
            <path fill="currentColor"
              d="M508.5 468.9L387.1 347.5c-2.3-2.3-5.3-3.5-8.5-3.5h-13.2c31.5-36.5 50.6-84 50.6-136C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c52 0 99.5-19.1 136-50.6v13.2c0 3.2 1.3 6.2 3.5 8.5l121.4 121.4c4.7 4.7 12.3 4.7 17 0l22.6-22.6c4.7-4.7 4.7-12.3 0-17zM208 368c-88.4 0-160-71.6-160-160S119.6 48 208 48s160 71.6 160 160-71.6 160-160 160z">
            </path>
          </svg></button><input type="text" placeholder="Search" name="fulltext_search" class="w-100 search-modal-input"></div>
    </div>
    <div class="row search-help-text font-weight-light text-align-left">
      <div class="col-md-10"> Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms. <br> Example: +water -Europe </div>
    </div>
  </div>
</form>

GET /search-results

<form action="/search-results" class="search-form row d-flex align-items-center position-relative" method="get">
  <div class="col-auto px-2 d-flex justify-content-center align-items-center position-absolute" style="z-index: 1;"><button type="submit"><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="search"
        class="svg-inline--fa fa-search fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512">
        <path fill="currentColor"
          d="M508.5 468.9L387.1 347.5c-2.3-2.3-5.3-3.5-8.5-3.5h-13.2c31.5-36.5 50.6-84 50.6-136C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c52 0 99.5-19.1 136-50.6v13.2c0 3.2 1.3 6.2 3.5 8.5l121.4 121.4c4.7 4.7 12.3 4.7 17 0l22.6-22.6c4.7-4.7 4.7-12.3 0-17zM208 368c-88.4 0-160-71.6-160-160S119.6 48 208 48s160 71.6 160 160-71.6 160-160 160z">
        </path>
      </svg></button></div>
  <div class="col p-0"><input type="text" placeholder="Search" name="fulltext_search" class="w-100 gray-bg font-weight-medium"></div>
</form>

Text Content

Advertisement



Fierce Biotech Continues Here ▼









 * Fierce Pharma
 * Fierce Biotech
 * Fierce Healthcare
 * Fierce Life Sciences Events


 * Research
 * Biotech
   * Clinical Data
   * Venture Capital
   * Deals
 * Medtech
   * Devices
   * Diagnostics
   * AI and Machine Learning
 * CRO
 * Special Reports
 * Trending Topics
   * Cell & Gene Therapy
   * COVID-19
   * Emerging Biopharma
   * Decentralized Trials
 * Podcasts

 * Resources
   * Events
   * Webinars
 * Subscribe

What are you searching for?


Enclose phrases in quotes. Use a + to require a term in results and - to exclude
terms.
Example: +water -Europe
Subscribe

 * Research
 * Biotech
   * Clinical Data
   * Venture Capital
   * Deals
   
 * Medtech
   * Devices
   * Diagnostics
   * AI and Machine Learning
   
 * CRO
 * Special Reports
 * Trending Topics
   * Cell & Gene Therapy
   * COVID-19
   * Emerging Biopharma
   * Decentralized Trials
   
 * Podcasts

 * Resources
   * Events
   * Webinars
   
 * Subscribe

 * Fierce Pharma
 * Fierce Biotech
 * Fierce Healthcare
 * Fierce Life Sciences Events



Biotech


BANCEL HAS 'NEVER BEEN AS BUSY' AMID M&A TALKS AS MODERNA PREPS FOR LIFE AFTER
COVID

By Max BayerMay 4, 2022 03:19pm
ModernaEarningsmergers and acquisitionsStéphane Bancel
Moderna CEO Stéphane Bancel wouldn’t dive deep into the qualifications of a
potential buy but said the company was looking worldwide and across therapeutic
areas.  (Bertrand Guay/AFP)

Moderna is prepping for life after COVID, and CEO Stéphane Bancel says he's
"never been as busy" as the company considers potential M&A opportunities.






“We will not be shy to invest to expand the platform either through technology
or through products,” Bancel said during the company's first-quarter earnings
report Wednesday. “And that’s really where we are in terms of M&A.” 



Moderna has experienced rapid, maybe even unprecedented, growth of 2,000% for
2021 compared to 2020, opening up a whole new world of acquisition
opportunities. Bancel wouldn’t dive deep into the qualifications of a potential
buy but said the company was looking worldwide and across therapeutic areas. 



whitepaper


UTILIZING AUGMENTED INTELLIGENCE TO DRIVE OPTIMAL DECISIONS THROUGHOUT THE
SPECIALTY AND RARE DISEASE PRODUCT LIFECYCLE

Sponsored by IPM.ai

For the development and commercialization of life improving therapies for rare
diseases, the typical approach falls short. Enter augmented intelligence, a
concept that utilizes ML/AI and RWD to enhance, rather than replace human
decision-making.

LEARN MORE

"In terms of M&A, I can tell you, our teams—I have never been as busy—they are
looking at a lot of opportunities literally across the world," Bancel said. 

Last year, Moderna pledged to “expand our horizons” with M&A, flagging nucleic
acid technologies, gene therapy, gene editing and mRNA as areas of interest. 


RELATED

Does the world need more COVID-19 vaccines? These companies think there's still
room for improvement

Moderna well exceeded earnings projections on the back of the COVID vaccine
Spikevax, according to the first-quarter report. But with the pandemic turning a
corner to endemic, the company made sure to profile other areas of its business.



The company now has a wide-open plan to consider where to go next outside the
vaccine program. Executives highlighted the rare disease program as an area they
hope to grow with similar fervor. Two phase 1 trials are currently ongoing in
propionic acidemia (PA) and methylmalonic acidemia (MMA); the former has already
achieved a fully enrolled first cohort and additional patients are being added.
 

“Assuming this is positive, we will do more in rare genetic disease,” said
Bancel. 

Moderna’s President Stephen Hoge said that the PA and MMA programs, should they
be successful, will validate the technology that could then be used to rapidly
expand the number of rare diseases Moderna targets. 

“But obviously if we have a very strong signal out of PA, we will be un-gating
other programs that can benefit from the technology that will then be de-risked
from the PA program,” he said. 


RELATED

Moderna taps Carnegie Mellon for in-house AI training academy

With that said, executives still touted the vaccine program, which currently
remains the bedrock of Moderna's pipeline even outside of COVID, particularly
the flu jab, mRNA-1010. The company expects to launch into a phase 3
immunogenicity study for that shot in the coming weeks before pursuing an
accelerated approval nod with regulators (although the FDA was not explicitly
mentioned).

Fierce Event

REGISTER NOW FOR EARLY-BIRD SAVINGS!

October 18-20, 2022

Philadelphia, PA

Register

Moderna is also prepping a phase 3 efficacy trial “if needed”; however, the
trial is less “if” and more "when," according to Hoge. In the event that
regulators nix accelerated approval, the company will launch the efficacy trial
to nab full approval, or that trial will act as a confirmatory study following
accelerated approval.

Biotechflu vaccineCOVID-19rare diseasesFood and Drug Administration (FDA)biotech
deals

Our Newsletter






RELATED ARTICLES

BD tightens up revenue guidance after completing Embecta diabetes spinoff
May 5, 2022 11:24am
BioCryst's voluntary pause turns FDA-hold as investigation reveals likely
culprit behind safety signals
May 5, 2022 11:11am
Intellia puts pedal to the metal as 3 new candidates prepped for clinic
May 5, 2022 11:00am
BerGenBio shifts focus from COVID—to COVID in new business strategy update
May 5, 2022 10:57am
See more articles
 * Connect
   * The Team
   * Advertise
 * Join Us
   * Newsletters
   * Resources
   * RSS Feeds
 * Our Brands
   * Fierce Pharma
   * Fierce Biotech
   * Fierce Healthcare
 * Our Events
   * Life Sciences Events

 * ©2022 Questex LLC All rights reserved.
 * Terms of use
 * Privacy Policy


ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789-_~x